Citations

Showing 10 of 108081 citations.

Faculty Opinions recommendation of A NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of colorectal resection.
Chua, Heidi K

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727525135.793531034 Get It

Faculty Opinions recommendation of Controversies in the oncosurgical management of liver limited stage IV colorectal cancer.
Chua, Heidi K

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727525080.793531032 Get It

Faculty Opinions recommendation of Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases.
Chua, Heidi K

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726483841.793531038 Get It

Faculty Opinions recommendation of Outcomes of simultaneous major liver resection and colorectal surgery for colorectal liver metastases.
Chua, Heidi K

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726067139.793531035 Get It

Faculty Opinions recommendation of Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.
Chua, Heidi K

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725837306.793531033 Get It

Faculty Opinions recommendation of Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients.
Chua, Heidi K

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718208800.793531039 Get It

The Incidence of and Risk Factors for Postintubation Hypotension in the Immunocompromised Critically Ill Adult
Seisa, Mohamed O. , Cambest, John, Wiegand, Robert A., Busack, Kyle D., Loftsgard, Theodore O. , Schroeder, Darrell R. , Diedrich, Daniel A. , Smischney, Nathan J. , Schroeder, Darrell

Mayo Clinic

Journal of Intensive Care Medicine | April 20, 2017 | Volume: 34 | Issue: 7 | Pages: 578-586

10.1177/0885066617704844 | PMID 28425335 Get It

Objectives: Our primary aim was to ascertain the frequency of postintubation hypotension in immunocompromised critically ill adults with secondary aims of arriving at potential risk factors for the development of postintubation hypotension and its impact on patient-related outcomes. Methods: Critically ill adult patients (≥18 years) were included from January 1, 2010, to December 31, 2014. We defined immunocompromised as patients with any solid organ or nonsolid organ malignancy or transplant, whether solid organ or not, requiring current chemotherapy. Postintubation hypotension was defined as a decrease in systolic blood pressure to less than 90 mm Hg or a decrease in mean arterial pressure to less than 65 mm Hg or the initiation of any vasopressor medication. Patients were then stratified based on development of postintubation hypotension. Potential risk factors and intensive care unit (ICU) outcome metrics were electronically captured by a validated data mart system. Results: The final cohort included 269 patients. Postintubation hypotension occurred in 141 (52%; 95% confidence interval: 46-58) patients. Several risk factors predicted postintubation hypotension on univariate analysis; however, only Acute Physiology and Chronic Health Evaluation III score in the first 24 hours, preintubation shock status, and preintubation hemodynamic instability remained significant on all 4 multivariate analyses. Patients developing postintubation hypotension had higher ICU and hospital mortality (54 [38%] vs 31 [24%], P = .01; 69 [49%] vs 47 [37%], P = .04). Conclusion: Based on previous literature, we found a higher frequency of postintubation hypotension in the immunocompromised than in the nonimmunocompromised critically ill adult patients. Acute Physiology and Chronic Health Evaluation III score in the first 24 hours, preintubation shock status, and preintubation hemodynamic instability were significant predictors on multivariate analyses. Postintubation hypotension led to higher ICU and hospital mortality in those experiencing this complication.
Recurrent myxoinflammatory fibroblastic sarcoma: a case report
Jagadesh, Niveditha , Miller, Daniel , Schenk, William B., Attia, Steven , Sherman, Courtney E. , Cortese, Cherise , May, Byron C. , Miller, Daniel H , Schenk, William, Miller, Robert C.

Mayo Clinic

Clinical Case Reports | April 20, 2017 | Volume: 5 | Issue: 6 | Pages: 871-875

10.1002/ccr3.949 | PMID 28588829 Get It

Key Clinical Message Myxoinflammatory fibroblastic sarcoma is a rare sarcoma which typically presents in the extremities and is treated by definitive surgery. In recurrent disease, the reported utilization of radiotherapy is increasing, and more modern techniques such as intensity‐modulated radiotherapy may be improving long‐term outcomes.
Nrf2, cellular redox regulation, and neurologic implications
Benarroch, Eduardo E.

Mayo Clinic

Neurology | April 20, 2017 | Volume: 88 | Issue: 20 | Pages: 1942-1950

10.1212/wnl.0000000000003946 | PMID 28424271 Get It

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
LaPlant, Betsy, Call, Timothy G. , Leis, José F., He, Rong , Wiseman, Gregory A., Lin, Yi , Asmus, Erik, Nowakowski, Grzegorz S. , Conte, Michael, Bowen, Deborah A., Aitken, Casey N., Dyke, Daniel L. Van , Greipp, Patricia T. , Wu, Xiaosheng , Secreto, Charla, Tian, Shulan , Braggio, Esteban , Wellik, Linda, Micallef, Ivana N. , Viswanatha, David S., Yan, Huihuang , Chanan‐Khan, Asher , Ansell, Stephen M. , LaPlant, Betsy R, Chanan-Khan, Asher A., Ding, Wei , Parikh, Sameer A. , Shanafelt, Tait D. , Sinha, Sutapa , Le‐Rademacher, Jennifer , Feldman, Andrew L. , Habermann, Thomas M. , Witzig, Thomas E. , Liu, Xin , Zhang, Henan , Kay, Neil E. , Dong, Haidong , Braggio, Esteban , Greipp, Patricia T , Lin, Yi

Mayo Clinic

Blood | April 20, 2017 | Volume: 129 | Issue: 26 | Pages: 3419-3427

10.1182/blood-2017-02-765685 | PMID 28424162 Get It

Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.